Phase II trial of esorubicin in patients with advanced melanoma.
D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged
D004317:Doxorubicin; C030851:esorubicin